Skip to main content

Huntington's Disease

Neurology
15
Pipeline Programs
23
Companies
24
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
3
7
0
1
1
Early DiscoveryClinical DevelopmentMarket

Neurology is a $26.9B market dominated by a single blockbuster anticoagulant (ELIQUIS), representing a mature but consolidating therapeutic area.

$26.9B marketMature→ Stable30 products15 companies

Key Trends

  • Extreme market concentration: 68% of spending driven by one FXa inhibitor product
  • Psychiatric and migraine therapies emerging as secondary growth drivers
  • High clinical trial activity (8,279 trials) signals continued pipeline development

Career Verdict

Neurology offers solid career stability with good hiring demand, but limited upside growth—best suited for professionals seeking established market positions rather than emerging-area innovation.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1ELIQUISStable
$18.3B
Bristol Myers Squibb·Launch15.0yr
$1.8B
#3BRILINTAStable
$692M
AstraZeneca·Peak10.2yr
#4NUPLAZIDStable
$596M
$530M
Johnson & Johnson·Peak15.6yr

Drug Class Breakdown

FXa Inhibitors (anticoagulant)
$18.3B(68%)

market-defining single product

Dopamine/Serotonin Antagonists (psychiatric)
$2.4B(9%)

stable mature class

P2Y12 Receptor Antagonists (antiplatelet)
$692M(3%)

niche but stable

5-HT2A Inverse Agonists (psychiatric)
$596M(2%)

specialty indication focus

CGRP Receptor Antagonists (migraine)
$931M(3%)

emerging growth segment

Immunomodulators (MS)
$747M(3%)

stable with LOE risk

Other mechanisms
$2.6B(10%)

diverse small products

Career Outlook

Stable

Neurology represents a mature, cash-generative market with limited growth tailwinds but strong hiring stability. The dominance of ELIQUIS creates a bifurcated career landscape: high-opportunity positions in emerging segments (CGRP antagonists, psychiatric therapeutics) and commoditized roles in anticoagulant franchises. Job availability is solid but growth expectations should be tempered relative to oncology or immunology.

Breaking In

Entry-level professionals should target clinical operations or commercial support roles at J&J, AstraZeneca, or Sanofi to build domain expertise in neurology disease states and competitive dynamics.

For Experienced Professionals

Experienced professionals should prioritize emerging mechanism roles (CGRP, tau-targeting programs) or pivot to medtech/neurotech (Stryker, Medtronic) to capture higher growth and salary potential than traditional pharma incumbents.

In-Demand Skills

Medical Science Liaisons (MSL) for specialist engagementClinical trial operations expertisePsychiatric/neurodegenerative disease educationRegulatory affairs (given patent cliff activity)Commercial strategy around branded/generic transitions

Best For

Medical Science LiaisonCommercial Brand Manager (anticoagulant/psychiatric franchises)Clinical Operations ManagerRegulatory Affairs SpecialistClinical Development Manager (CGRP/immunomodulator pipelines)

Hiring Landscape

$100K-$199K

Neurology shows moderate but distributed hiring across pharma and medtech employers, with 4,186 total jobs listed. Commercial functions lead (947 roles, $169K avg), followed by clinical operations (467 roles, $132K avg), indicating bias toward commercialization over R&D. Takeda leads external hiring (762 jobs) with strong representation in contract research and CRO spaces.

4,186
Open Roles
5
Companies Hiring
5
Departments

Top Hiring Companies

762Growing
434Stable
302Stable

By Department

Commercial(23%)
$169K
Clinical Operations(11%)
$132K
Engineering(8%)
$199K
IT(4%)
$100K
Manufacturing(3%)
$170K

Commercial and clinical operations roles dominate, offering stable mid-career positions; engineering roles command premium salaries ($199K), suggesting strong device/neurotech hiring pockets.

Competitive Landscape

20 companies ranked by most advanced pipeline stage

Lundbeck
LundbeckDenmark - Copenhagen
1 program
1
TetrabenazinePhase 41 trial
Active Trials
NCT02509793Unknown20Est. Jul 2023
Supernus Pharmaceuticals
2 programs
1
1
SAGE-718Phase 31 trial
SAGE-718Phase 21 trial
Active Trials
NCT05107128Completed189Est. Oct 2024
NCT05655520Terminated153Est. Jan 2025
Genentech
GenentechCA - Oceanside
2 programs
1
1
RO7234292Phase 21 trial
No Study Drug was Administered in this StudyPhase 11 trial
Active Trials
NCT03664804Completed95Est. May 2022
NCT03342053Completed46Est. Oct 2019
Pfizer
PfizerNEW YORK, NY
2 programs
2
PF-02545920Phase 21 trial
PF-02545920Phase 21 trial
Active Trials
NCT02197130Completed272Est. Oct 2016
NCT01806896Completed37Est. Jan 2015
Prilenia Therapeutics
Prilenia TherapeuticsIsrael - Herzliya
2 programs
2
PridopidinePhase 21 trial
PridopidinePhase 21 trial
Active Trials
NCT02494778Terminated248Est. Jan 2018
NCT02006472Completed408Est. Jul 2016
Sandoz
SandozAustria - Kundl
1 program
1
AFQ056Phase 21 trial
Active Trials
NCT01019473Terminated44
WaVe Life Sciences
WaVe Life SciencesJapan - Kagoshima
2 programs
2
WVE-120101Phase 1/21 trial
WVE-120102Phase 1/21 trial
Active Trials
NCT03225833Terminated61Est. May 2021
NCT03225846Terminated88Est. May 2021
uniQure
uniQureNetherlands - Amsterdam
1 program
1
intra-striatal rAAV5-miHTTPhase 1/21 trial
Active Trials
NCT04120493Active Not Recruiting43Est. Dec 2029
Alnylam Pharmaceuticals
1 program
1
ALN-HTT02Phase 11 trial
Active Trials
NCT06585449Recruiting66Est. Jul 2028
Palo BioFarma
Palo BioFarmaSpain - Barcelona
1 program
1
PBF-999Phase 11 trial
Active Trials
NCT02208934Completed32Est. Oct 2015
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's DiseaseN/A1 trial
Long-Term Study of Cerebral Glucose Metabolism in Huntington's DiseaseN/A1 trial
Active Trials
NCT00670709Completed42Est. Feb 2008
NCT00004753Completed90
Roche
RocheSTAVANGER NORWAY, Norway
2 programs
No Study Drug was Administered in this StudyPHASE_1
RO7234292PHASE_2
Gloria Biosciences
Gloria BiosciencesChina - Guangzhou
1 program
Computerised cognitive trainingN/A1 trial
Active Trials
NCT02990676Completed30Est. Mar 2019
Pins Medical
Pins MedicalChina - Beijing
1 program
Deep Brain StimulationN/A1 trial
Active Trials
NCT02263430Unknown8Est. Dec 2018
Q Therapeutics
Q TherapeuticsUT - Salt Lake City
1 program
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's DiseaseN/A
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
FuRST 2.0N/A1 trial
Active Trials
NCT02881931CompletedEst. Jul 2017
Ionis Pharmaceuticals
1 program
ISIS 443139 10 mgPHASE_1_21 trial
Active Trials
NCT02519036Completed46Est. Nov 2017
Ipsen
IpsenChina - Tianjin
1 program
BN82451BPHASE_21 trial
Active Trials
NCT02231580Terminated17Est. Mar 2016
Teva
TevaIsrael - Petach Tikva
1 program
LaquinimodPHASE_21 trial
Active Trials
NCT02215616Completed352Est. Jun 2018
Vaccinex
VaccinexROCHESTER, NY
1 program
VX15/2503PHASE_21 trial
Active Trials
NCT02481674Completed301Est. Aug 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
LundbeckTetrabenazine
Supernus PharmaceuticalsSAGE-718
Supernus PharmaceuticalsSAGE-718
GenentechRO7234292
Prilenia TherapeuticsPridopidine
VaccinexVX15/2503
TevaLaquinimod
PfizerPF-02545920
IpsenBN82451B
Prilenia TherapeuticsPridopidine
PfizerPF-02545920
SandozAFQ056
uniQureintra-striatal rAAV5-miHTT
WaVe Life SciencesWVE-120101
WaVe Life SciencesWVE-120102

Showing 15 of 24 trials with date data

Clinical Trials (24)

Total enrollment: 2,688 patients across 24 trials

NCT02509793LundbeckTetrabenazine

A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)

Start: Aug 2018Est. completion: Jul 202320 patients
Phase 4Unknown

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease

Start: Dec 2022Est. completion: Jan 2025153 patients
Phase 3Terminated

A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)

Start: Jan 2022Est. completion: Oct 2024189 patients
Phase 2Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

Start: Jan 2018Est. completion: Oct 201946 patients
Phase 2Completed

A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease

Start: Sep 2015Est. completion: Jan 2018248 patients
Phase 2Terminated

A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

Start: Jul 2015Est. completion: Aug 2020301 patients
Phase 2Completed
NCT02215616TevaLaquinimod

A Clinical Study in Participants With Huntington's Disease (HD) to Assess Efficacy and Safety of Three Oral Doses of Laquinimod

Start: Oct 2014Est. completion: Jun 2018352 patients
Phase 2Completed

Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease

Start: Sep 2014Est. completion: Oct 2016272 patients
Phase 2Completed

Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients

Start: Sep 2014Est. completion: Mar 201617 patients
Phase 2Terminated

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

Start: Feb 2014Est. completion: Jul 2016408 patients
Phase 2Completed

Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease

Start: Sep 2013Est. completion: Jan 201537 patients
Phase 2Completed

Efficacy, Safety and Tolerability of AFQ056 in Patients With Huntington's Disease in Reducing Chorea

Start: Nov 200944 patients
Phase 2Terminated
NCT04120493uniQureintra-striatal rAAV5-miHTT

Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease

Start: Sep 2019Est. completion: Dec 202943 patients
Phase 1/2Active Not Recruiting

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Start: Jul 2017Est. completion: May 202161 patients
Phase 1/2Terminated

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Start: Jul 2017Est. completion: May 202188 patients
Phase 1/2Terminated

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Start: Aug 2015Est. completion: Nov 201746 patients
Phase 1/2Completed

A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease

Start: Oct 2024Est. completion: Jul 202866 patients
Phase 1Recruiting
NCT03664804GenentechNo Study Drug was Administered in this Study

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

Start: Dec 2018Est. completion: May 202295 patients
Phase 1Completed

Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers

Start: Sep 2014Est. completion: Oct 201532 patients
Phase 1Completed

FuRST 2.0 Cognitive Pre-Testing

Start: Feb 2017Est. completion: Jul 2017
N/ACompleted
NCT02990676Gloria BiosciencesComputerised cognitive training

Exploring Computerised Cognitive Training for People With Huntington's Disease

Start: Jan 2017Est. completion: Mar 201930 patients
N/ACompleted
NCT02263430Pins MedicalDeep Brain Stimulation

PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease

Start: Dec 2016Est. completion: Dec 20188 patients
N/AUnknown
NCT00670709Angeles TherapeuticsExamination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease

Start: Sep 2006Est. completion: Feb 200842 patients
N/ACompleted
NCT00004753Angeles TherapeuticsLong-Term Study of Cerebral Glucose Metabolism in Huntington's Disease

Long-Term Study of Cerebral Glucose Metabolism in Huntington's Disease

Start: Aug 199390 patients
N/ACompleted

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 2,688 patients
23 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.